Kindred Biosciences (NASDAQ: KIN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.
This is a summary of recent ratings and target prices for Kindred Biosciences and Rigel Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kindred Biosciences currently has a consensus price target of $9.90, indicating a potential upside of 15.79%. Rigel Pharmaceuticals has a consensus price target of $5.80, indicating a potential upside of 46.84%. Given Rigel Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Kindred Biosciences.
Insider & Institutional Ownership
66.6% of Kindred Biosciences shares are owned by institutional investors. Comparatively, 74.1% of Rigel Pharmaceuticals shares are owned by institutional investors. 19.1% of Kindred Biosciences shares are owned by insiders. Comparatively, 5.2% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Kindred Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
Earnings & Valuation
This table compares Kindred Biosciences and Rigel Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kindred Biosciences||N/A||N/A||-$22.49 million||($1.17)||-7.31|
|Rigel Pharmaceuticals||$20.38 million||28.39||-$69.21 million||($0.59)||-6.69|
Kindred Biosciences has higher earnings, but lower revenue than Rigel Pharmaceuticals. Kindred Biosciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Kindred Biosciences and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Rigel Pharmaceuticals beats Kindred Biosciences on 8 of the 12 factors compared between the two stocks.
About Kindred Biosciences
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.